Virion Therapeutics raises $4M to continue work on cancer, viral infection treatments - Technical.ly Philly

Business

Sep. 17, 2018 9:37 am

Virion Therapeutics raises $4M to continue work on cancer, viral infection treatments

The Philly company, a spinout of the Wistar Institute, got backing from Robin Hood Ventures, Keiretsu Forum and Mid-Atlantic Bio Angels Group.

The Wistar Institute.

(Courtesy photo)

Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing.

The immunotherapy company is working on a path to commercialization for a set of vaccines aimed at treating certain types of cancers and chronic viral infections.

Cofounded by Wistar Institute professor Hildegund C.J. Ertl, Andrew Luber and Bernie Rudnick, the company is working on scientific assets that have been backed by some $25 million in grants.

The Philly-based company will use the funds to complete an FDA Investigational New Drug (IND) filing for its lead HPV vaccine candidate, and perform preclinical work on another vaccine for chronic HBV infection.

“We believe our checkpoint inhibitor has significant advantages over other agents in one of the most rapidly growing segments, immuno-oncology,” cofounder and CEO Rudnick said in a statement. “Our goals are to collaborate with major pharmaceutical companies in commercializing our vaccines, save lives and build a desirable business for near term exits with robust investment returns.”

Rudnick is also a member investor of Robin Hood Ventures, which joined the round with $417,000. Mid-Atlantic Bio Angels Group (MABA), Life Science Angels, Keiretsu Forum, Alliance of Angels and Crimson Peak also invested in the round, which the company expects will exceed $5 million upon final closing.

Investor Rena Rosenberg, a Robin Hood Ventures partner who co-led the Virion investment, said the experience of the company’s leadership made the case for the investment.

“If there is a team that is capable of identifying potential solutions in many of these infection-based cancers, this is the group of individuals that you want,” Rosenberg said.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Why Philly made sense for Johnson & Johnson’s first innovation office

‘Convenient’ Philly lands at No. 8 on Forbes list of top startup cities

New Jersey is planning a $500-million fund to back startups

SPONSORED

Philly

Clients and community come first for Vanguard employees

Malvern, PA

Vanguard

Sr. Full Stack Developer-Client Experience Lab

Apply Now
Malvern, PA

Vanguard

Product Owner of Data Science Solutions

Apply Now
Malvern, PA

Vanguard

Java Developer-Entry

Apply Now

‘The Theranos fiasco’ didn’t stop Group K Diagnostics from raising $800,000

How do investors decide to go all in? Ask Brett Topche at Startup Grind

NeuroFlow just raised $1.2 million to scale up

SPONSORED

Philly

UX, UArts and the importance of human-centered design

Malvern, PA

Vanguard

Technical Lead-Full Stack

Apply Now
Center City Area

Inspire

Product Manager

Apply Now
Chesterbrook, PA

Deacom

Creative Content Writer – Tech

Apply Now

Sign-up for daily news updates from Technical.ly

Do NOT follow this link or you will be banned from the site!